Cyclacel Pharmaceuticals Inc logo

Cyclacel Pharmaceuticals Inc

NAS:CYCC (USA)  
$ 1.65 +0.11 (+7.14%) 04:00 PM EST
At Loss
Enterprise V:
$ -524.00K
Volume:
134.44K
Avg Vol (2M):
173.73K
Trade In:
Volume:
134.44K
At Loss
Avg Vol (2M):
173.73K

Business Description

Description
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Name Current Vs Industry Vs History
Cash-To-Debt 133.24
Equity-to-Asset -0.36
Debt-to-Equity -0.01
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -110.54
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 38.62
9-Day RSI 40.71
14-Day RSI 42.11
6-1 Month Momentum % -33.45
12-1 Month Momentum % -78.97

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.58
Quick Ratio 0.58
Cash Ratio 0.34

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -36.5
Shareholder Yield % 2.55
Name Current Vs Industry Vs History
Operating Margin % -5008.69
Net Margin % -4386.86
FCF Margin % -2167.93
ROE % -365.16
ROA % -149.29
ROIC % -974.64
ROC (Joel Greenblatt) % -17820.13
ROCE % -413.01

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 3.15
EV-to-EBIT 0.02
EV-to-EBITDA 0.02
EV-to-Revenue -1.17
EV-to-Forward-Revenue 0.03
EV-to-FCF 0.05
Earnings Yield (Greenblatt) % 5000
FCF Yield % -403.06

Financials (Next Earnings Date:2024-08-09 Est.)

CYCC's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:CYCC

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Cyclacel Pharmaceuticals Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.449
EPS (TTM) ($) -22.3
Beta 0.09
Volatility % 105.65
14-Day RSI 42.11
14-Day ATR ($) 0.160018
20-Day SMA ($) 1.627645
12-1 Month Momentum % -78.97
52-Week Range ($) 1.3 - 13.199999
Shares Outstanding (Mil) 1.46

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Cyclacel Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Cyclacel Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Cyclacel Pharmaceuticals Inc Frequently Asked Questions

What is Cyclacel Pharmaceuticals Inc(CYCC)'s stock price today?
The current price of CYCC is $1.65. The 52 week high of CYCC is $13.20 and 52 week low is $1.30.
When is next earnings date of Cyclacel Pharmaceuticals Inc(CYCC)?
The next earnings date of Cyclacel Pharmaceuticals Inc(CYCC) is 2024-08-09 Est..
Does Cyclacel Pharmaceuticals Inc(CYCC) pay dividends? If so, how much?
Cyclacel Pharmaceuticals Inc(CYCC) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1